Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It
aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for
subjects who completed the core study CAIN457F2306, to obtain further long term efficacy,
safety and tolerability information in subjects with active psoriatic arthritis receiving
secukinumab every 4 weeks. At Week 104 of the study CAIN457F2306, eligible subjects completed
the assessments associated with the core study visit and subsequently continued in this
extension study on the same dose that they were receiving during the core study. The regular
assessments of disease activity ensure that subjects who are experienced worsening of disease
in any of the treatment groups could exit the study upon their own wish or based on the
advice of the investigator at any time.